Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY: LLY )

298.85 UNCHANGED
Streaming Delayed Price Updated: 4:10 PM EDT, May 20, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Eli Lilly

< Previous 1 2 3 4 5 6 7 8 9
...
17 18 Next >
FDA Says Current Dose Of GSK-Vir's COVID-19 Therapy Unlikely To Work Against Omicron Subvariant
 
Via Benzinga
Incyte-Lilly's Olumiant Continue To Show Improved Scalp, Eyebrows, Eyelash Hair Regrowth At 52 Weeks
At the American Academy of Dermatology Annual Meeting, Eli Lilly And Co (NYSE: LLY) and Incyte Corp (NASDAQ: INCY)  
Via Benzinga
Week In Review: Nuance In-Licenses RSV Vaccine In $225 Million Deal
Shanghai Nuance Pharma in-licensed China and Southeast Asia rights to a respiratory syncytial virus (RSV) vaccine from Copenhagen’s Bavarian Nordic in a $225 million deal. The vaccine is aimed at older... 
Via Talk Markets
How Rivals Merck, Bristol Myers Benefit From Eli Lilly's FDA Snag
The Food and Drug Administration on Thursday rejected a lung cancer drug Eli Lilly tested only in China, but LLY stock inched higher. 
Via Investor's Business Daily
FDA Rejects Lilly's Sintilimab/Chemo Combo Therapy In First-Line Lung Cancer Setting
The  
Via Benzinga
The Daily Biotech Pulse: Novartis Prostate Cancer Drug Lands FDA Approval, Ligand Announces SPAC Deal To Spin Off Antibody Business, Lilly's Lung Cancer Therapy Hit With CRL
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Insiders Sell About $138M Of 5 Stocks
The Russian ruble declined against the US dollar on Monday after the Moscow Exchange resumed trading of government debt securities. Investors, meanwhile, focused on some notable... 
Via Benzinga
Looking Into Eli Lilly and Company's Recent Short Interest
Eli Lilly and Company's (NYSE:LLY) short percent of float has risen 13.56% since its last report. The company recently reported that it has 5.36 million shares sold short, which... 
Via Benzinga
World Markets News For Friday
Buoyant global markets are closing the week and one good performer, Vir Biotech, today gained an impressive 6.09%. 
Via Talk Markets
Check Out What Whales Are Doing With LLY
Someone with a lot of money to spend has taken a bearish stance on Eli Lilly (NYSE:LLY). And retail traders should know. We noticed this today when the big position showed up on publicly available... 
Via Benzinga
Watch For Continued Gains In Shares Of Eli Lilly And Company
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. Eli Lilly and Company (NYSE: LLY) ... 
Via Benzinga
Markets Rise
Markets in Asia and Europe rose today in hopes for the Chinese to provide economic support to these markets after it paid its bond debt. 
Via Talk Markets
Eli Lilly's Phase 3 Jardiance Study Stopped Early Due To Clear Positive Efficacy In Kidney Disease
 Based on the Independent Data Monitoring Committee's recommendation, Boehringer Ingelheim and Eli Lilly And Co (NYSE: LLY) will stop early its EMPA-KIDNEY trial of Jardiance (empagliflozin) in adults... 
Via Benzinga
News-Filled Day
The price of oil fell to below $100/oz on the prospect of lower demand from the PRC. 
Via Talk Markets
Eli Lilly To Suspend Sale Of 'Non-Essential' Medicines To Russia
Eli Lilly And Co (NYSE: LLY) said it would continue to supply drugs to Russia for urgent medical conditions such as cancer and diabetes but will suspend sales of "non-essential medicines." 
Via Benzinga
Executives Sell More Than $25M Of 4 Stocks
Although US crude oil futures traded sharply on Tuesday, there were a few notable insider trades. When insiders sell shares, it indicates their concern in the company’s... 
Via Benzinga
Big U.S. Stocks’ Q4’21 Fundamentals
U.S. stock markets have suffered a major trend reversal this year, rolling over into a full-blown correction. 
Via Talk Markets
Bristol Myers, Eli Lilly And 2 Others Prove You Can Still Make Money In Medical Stocks
These four medical stocks are outperforming the lousy market for health care investors. 
Via Investor's Business Daily
Here's How Much $100 Invested In Eli Lilly 5 Years Ago Would Be Worth Today
Eli Lilly (NYSE:LLY) has outperformed the market over the past 5 years by 13.68% on an annualized basis. Buying $100 In LLY: 5 years ago, an investor could have purchased 1.19... 
Via Benzinga
Meta Platforms And 4 Other Stocks Sold By Insiders
Although US crude oil futures traded higher this morning, there were a few notable insider trades. When insiders sell shares, it indicates their concern in the company’s... 
Via Benzinga
Eli Lilly's JAK Inhibitor Baricitinib Cuts Death Risk By 13% In COVID-19 Patients
According to a British study, Eli Lilly And Co (NYSE: LLY) and Incyte Corporation's (NASDAQ: INCY) Olumiant (baricitinib) reduced the risk of death in... 
Via Benzinga
36 Stocks To Watch After Biden's First State of The Union Address
President Joe Biden hosted his first State of the Union Address Tuesday in front of members of Congress. In the speech, Biden discussed several items that he has already helped... 
Via Benzinga
Eli Lilly And 3 Other Stocks Sold By Insiders
Although US crude oil futures traded higher this morning, there were a few notable insider trades. When insiders sell shares, it indicates their concern in the company’s... 
Via Benzinga
Does the FDA Rollback Of Regeneron And Eli Lilly COVID Treatment EUAs Signal A Need To Look Beyond Monoclonal Antibodies? NanoViricides, Inc. Looks To Meet This Need With A New Approach
Photo credit: Marcelo Leal and Kate Hliznitsova on Unsplash This post contains sponsored advertising content. This content is for informational purposes only and is not intended... 
Via Benzinga
The Week Ahead In Biotech (Feb. 27-March 5): Earnings, Multiple Regulatory Decisions Take The Spotlight
Biopharma stocks lock-stepped with the broader market in the week ending Feb. 25 before finishing higher. The trajectory was the same, with the sector declining in the first two sessions of the... 
Via Talk Markets
The Week Ahead In Biotech (Feb. 27-March 5): Earnings, Multiple Regulatory Decisions Take The Spotlight
Biopharma stocks lock-stepped with the broader market in the week ending Feb. 25 before finishing higher. The trajectory was the same, with the sector declining in the first... 
Via Benzinga
Eli Lilly Stock Shows Improved Relative Strength Performance With 84 RS Rating
Eli Lilly reached a key technical benchmark, with its Relative Strength Rating moving into the 80-plus percentile with an upgrade to 84. 
Via Investor's Business Daily
FDA Approves Eli Lilly's Jardiance In Broader Heart Patient Population
The FDA approved Eli Lilly And Co (NYSE: LLY) and partner Boehringer Ingelheim's drug, Jardiance, for expanded use in reducing the risk of death and... 
Via Benzinga
The Daily Biotech Pulse: Lilly's Jardiance Gets Nod For Heart Failure, Pulmatrix Announces Reverse Split, Reata Awaits FDA Decision
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Lilly's Co-developed Diabetes Drug Jardiance Gets Label Expansion To... 
Via Benzinga
Eli Lilly Bets On RNA Potential With $700M Investment In Boston's Seaport
Eli Lilly And Co (NYSE: LLY) will dole out $700 million for a new research site at Boston's Seaport district as part of the Company's broader push into RNA... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
17 18 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.